CME Information
Up to 3 AMA PRA Category 1 Credit(s)™
Release date: July 2007 Valid through: July 2008
Course Material: CME Monograph (PDF)
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
"Target Audience
This educational activity is intended for oncologists and other medical professionals who assess, counsel, and treat lung cancer patients.
Educational Objectives
After successfully completing this CME activity, participants should be able to:
- Discuss why vascular endothelial growth factor (VEGF) is considered to be an important target in lung cancer biology.
- Assess current efficacy and safety data for bevacizumab, as well as issues and opportunities for its use in treating patients with late-stage non-small cell lung cancer (NSCLC).
- Assess current efficacy and safety data for leading development-stage anti-VEGF agents in lung cancer treatment.
Educational Need
Medical professionals involved in treating lung cancer patients must understand why angiogenesis and VEGF are important targets in lung cancer and be able to assess clinical data for anti-VEGF agents, as well as opportunities and issues related to the integration of these agents into current practice.
Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity.
Educational Grant Support
Supported by an educational grant from Genentech.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
The program faculty have reported financial relationships with commercial pharmaceutical, device, or biotechnology companies as noted: Tracey Evans: Speakers’ Bureau: Eli Lilly, Genentech, sanofi-aventis. Rebecca Suk Heist: Nothing to disclose. Edward Kim: Nothing to disclose. Thomas Lynch, Jr: Speakers’ Bureau: AstraZeneca, Eli Lilly, Genentech, OSI, sanofi-aventis; Adviser: Boehringer Ingelheim, ImClone, sanofi-aventis; Consultant: Genentech, Millennium, Telik; Royalties: Genzyme. Mark Socinski: Speakers’ Bureau: AstraZeneca, Eli Lilly, Genentech, sanofi-aventis; Research funding: AstraZeneca, Eli Lilly, Genentech, Pfizer, sanofi-aventis. InforMEDical staff who contributed to planning and editing content, and individuals who provided independent peer review, have no financial relationships to disclose.
This educational activity may contain discussion of investigational uses of agents, devices, or diagnostic tools that have not been approved for use by the US Food and Drug Administration. The opinions expressed in the activity are those of the authors and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device, or diagnostic tool mentioned in this activity.